Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $19.20

Novavax, Inc. (NASDAQ:NVAXGet Free Report) has been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.00.

A number of research firms recently commented on NVAX. TD Cowen upgraded Novavax to a “hold” rating in a report on Thursday, February 27th. Citigroup began coverage on Novavax in a report on Tuesday. They issued a “sell” rating and a $6.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday, May 9th. B. Riley reiterated a “buy” rating on shares of Novavax in a report on Monday, May 19th. Finally, BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective on the stock.

Get Our Latest Analysis on Novavax

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Novavax during the fourth quarter worth $27,000. New Age Alpha Advisors LLC acquired a new position in Novavax during the fourth quarter worth $35,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Novavax during the first quarter worth $71,000. GAMMA Investing LLC lifted its stake in Novavax by 2,272.5% during the first quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 11,340 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Novavax by 290.1% during the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 7,940 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Performance

NVAX opened at $6.30 on Tuesday. Novavax has a one year low of $5.01 and a one year high of $17.81. The stock has a market capitalization of $1.02 billion, a PE ratio of 2.38, a P/E/G ratio of 0.07 and a beta of 2.80. The business’s 50 day moving average price is $6.73 and its 200 day moving average price is $7.65.

Novavax (NASDAQ:NVAXGet Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $2.22. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The firm had revenue of $666.66 million for the quarter, compared to analysts’ expectations of $204.08 million. During the same period in the prior year, the firm posted ($1.05) earnings per share. The firm’s quarterly revenue was up 610.3% on a year-over-year basis. As a group, equities research analysts forecast that Novavax will post -1.46 earnings per share for the current fiscal year.

Novavax Company Profile

(Get Free Report

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Featured Stories

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.